BAP1 Loss is a Useful Adjunct to Distinguish Malignant Mesothelioma Including the Adenomatoid-like Variant From Benign Adenomatoid Tumors.
Adenomatoid Tumor
/ diagnosis
Adolescent
Adult
Aged
Aged, 80 and over
Biopsy
Female
Gene Expression Regulation, Neoplastic
Humans
Lung Neoplasms
/ diagnosis
Male
Mesothelioma
/ diagnosis
Mesothelioma, Malignant
Middle Aged
Neoplasm Invasiveness
Tumor Suppressor Proteins
/ biosynthesis
Ubiquitin Thiolesterase
/ biosynthesis
Journal
Applied immunohistochemistry & molecular morphology : AIMM
ISSN: 1533-4058
Titre abrégé: Appl Immunohistochem Mol Morphol
Pays: United States
ID NLM: 100888796
Informations de publication
Date de publication:
01 2020
01 2020
Historique:
pubmed:
15
1
2019
medline:
24
11
2020
entrez:
15
1
2019
Statut:
ppublish
Résumé
Malignant mesothelioma (MM) can show areas closely mimicking reactive mesothelial proliferations or recapitulating benign adenomatoid tumors (ATs) making distinction on occasion impossible on morphologic ground alone, particularly in limited biopsy material. Recently, loss of BAP1 by immunohistochemistry (IHC) has been suggested as a potential marker for identifying MM, but data is still limited. We studied 264 MM cases (257 using tissue microarrays; 7 on conventional slides) and 42 genital ATs for BAP1 immunohistochemical expression. Loss of BAP1 protein expression was observed in 119/211 of MM cases (56.4%). Taken by histologic type, 64.3% of biphasic, 55.4% of epithelioid, and 41.7% of sarcomatoid MM were BAP1-deficient. In contrast, all 42 ATs showed retained BAP1 immunoreactivity. Notably, all 4 MM cases with variable adenomatoid-like features were BAP1-deficient. Surface components of MM of the pleura showed concordant loss as the invasive tumor suggesting a potential role for BAP1 loss for recognizing so-called early mesothelioma. In conclusion, BAP1 loss demonstrated by IHC is seen in more than half of MM cases but none of ATs. Thus, BAP1 IHC represents a potential adjunct for distinguishing MM from benign mesothelial proliferations including in particular "MM with bland adenomatoid-like pattern versus benign ATs" on biopsy material and early mesothelioma with limited invasion.
Identifiants
pubmed: 30640754
doi: 10.1097/PAI.0000000000000700
pii: 00129039-202001000-00011
doi:
Substances chimiques
BAP1 protein, human
0
Tumor Suppressor Proteins
0
Ubiquitin Thiolesterase
EC 3.4.19.12
Types de publication
Clinical Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
67-73Références
van Zandwijk N, Clarke C, Henderson D, et al. Guidelines for the diagnosis and treatment of malignant pleural mesothelioma. J Thorac Dis. 2013;5:E254–E307.
Goldblum J, Hart WR. Localized and diffuse mesotheliomas of the genital tract and peritoneum in women. A clinicopathologic study of nineteen true mesothelial neoplasms, other than adenomatoid tumors, multicystic mesotheliomas, and localized fibrous tumors. Am J Surg Pathol. 1995;19:1124–1137.
Allen TC, Cagle PT, Churg AM, et al. Localized malignant mesothelioma. Am J Surg Pathol. 2005;29:866–873.
Travis WD, Colby TV, Corrin B, et alTravis WD, Colby TV, Corrin B, Shimosato Y, Brambilla E. TNM classificationof malignant mesothelioma of the pleura. Histological Typing of Lung and Pleural Tumours. Berlin, Heidelberg: Springer Berlin Heidelberg; 1999:71–72.
Weissferdt A, Kalhor N, Suster S. Malignant mesothelioma with prominent adenomatoid features: a clinicopathologic and immunohistochemical study of 10 cases. Ann Diagn Pathol. 2011;15:25–29.
Arrossi AV, Lin E, Rice D, et al. Histologic assessment and prognostic factors of malignant pleural mesothelioma treated with extrapleural pneumonectomy. Am J Clin Pathol. 2008;130:754–764.
Husain AN, Colby TV, Ordonez NG, et al. Guidelines for pathologic diagnosis of malignant mesothelioma 2017 update of the consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med. 2018;142:89–108.
Amin W, Parwani AV. Adenomatoid tumor of testis. Clin Med Pathol. 2009;2:17–22.
Kontos S, Fokitis I, Karakosta A, et al. Adenomatoid tumor of epididymidis: a case report. Cases J. 2008;1:206.
Delahunt B, Eble JN, King D, et al. Immunohistochemical evidence for mesothelial origin of paratesticular adenomatoid tumour. Histopathology. 2000;36:109–115.
Nogales FF, Isaac MA, Hardisson D, et al. Adenomatoid tumors of the uterus: an analysis of 60 cases. Int J Gynecol Pathol. 2002;21:34–40.
Minato H, Kurose N, Fukushima M, et al. Comparative immunohistochemical analysis of IMP3, GLUT1, EMA, CD146, and desmin for distinguishing malignant mesothelioma from reactive mesothelial cells. Am J Clin Pathol. 2014;141:85–93.
Lee AF, Gown AM, Churg A. IMP3 and GLUT-1 immunohistochemistry for distinguishing benign from malignant mesothelial proliferations. Am J Surg Pathol. 2013;37:421–426.
Kadariya Y, Cheung M, Xu J, et al. Bap1 is a bona fide tumor suppressor: genetic evidence from mouse models carrying heterozygous germline Bap1 mutations. Cancer Res. 2016;76:2836–2844.
Jensen DE, Proctor M, Marquis ST, et al. BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression. Oncogene. 1998;16:1097–1112.
Ventii KH, Devi NS, Friedrich KL, et al. BRCA1-associated protein-1 is a tumor suppressor that requires deubiquitinating activity and nuclear localization. Cancer Res. 2008;68:6953–6962.
Betti M, Aspesi A, Biasi A, et al. CDKN2A and BAP1 germline mutations predispose to melanoma and mesothelioma. Cancer Lett. 2016;378:120–130.
Farzin M, Toon CW, Clarkson A, et al. Loss of expression of BAP1 predicts longer survival in mesothelioma. Pathology. 2015;47:302–307.
Cigognetti M, Lonardi S, Fisogni S, et al. BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations. Mod Pathol. 2015;28:1043–1057.
Joseph NM, Chen Y-Y, Nasr A, et al. Genomic profiling of malignant peritoneal mesothelioma reveals recurrent alterations in epigenetic regulatory genes BAP1, SETD2, and DDX3X. Mod Pathol. 2017;30:246–254.
McGregor SM, Dunning R, Hyjek E, et al. BAP1 facilitates diagnostic objectivity, classification, and prognostication in malignant pleural mesothelioma. Hum Pathol. 2015;46:1670–1678.
Berney D, Agaimy A, Amin MB, et alMoch H, Humphrey PA, Ulbright TM, Reuter VE. Tumours of paratesticular structures. WHO Classification of Tumours of the Urinary System and Male Genital Organs, 4th ed. Lyon: IARC Press; 2016;8:246–252.
Kurman RJ, Carcangiu ML, Herrington CS, et al. WHO Classification of Tumours of Female Reproductive Organs (Vol 6), 4th ed. Lyon: IARC Press; 2014.
Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG, eds. WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart (Vol 7), 4th ed. Lyon: IARC Press; 2015.
Wachter DL, Wunsch PH, Hartmann A, et al. Adenomatoid tumors of the female and male genital tract. A comparative clinicopathologic and immunohistochemical analysis of 47 cases emphasizing their site-specific morphologic diversity. Virchows Archiv. 2011;458:593–602.
Klebe S, Brownlee NA, Mahar A, et al. Sarcomatoid mesothelioma: a clinical-pathologic correlation of 326 cases. Mod Pathol. 2010;23:470–479.
Sandeck HP, Roe OD, Kjaerheim K, et al. Re-evaluation of histological diagnoses of malignant mesothelioma by immunohistochemistry. Diagn Pathol. 2010;5:47.
Hinterberger M, Reineke T, Storz M, et al. D2-40 and calretinin—a tissue microarray analysis of 341 malignant mesotheliomas with emphasis on sarcomatoid differentiation. Mod Pathol. 2007;20:248–255.
Kaplan MA, Tazelaar HD, Hayashi T, et al. Adenomatoid tumors of the pleura. Am J Surg Pathol. 1996;20:1219–1223.
Simpson PR. Adenomatoid tumor of the adrenal gland. Arch Pathol Lab Med. 1990;114:725–727.
Hanrahan JB. A combined papillary mesothelioma and adenomatoid tumor of the omentum; report of a case. Cancer. 1963;16:1497–1500.
Craig JR, Hart WR. Extragenital adenomatoid tumor: evidence for the mesothelial theory of origin. Cancer. 1979;43:1678–1681.
Stephnson TJ, Mills PM. Adenomatoid tumours: an immunohistochemical and ultrastructural appraisal of their htstogenests. J Pathol. 1986;148:327–335.
Yang LH, Yu JH, Xu HT, et al. Mesothelioma of the tunica vaginalis testis with prominent adenomatoid features: a case report. Int J Clin Exp Pathol. 2014;7:7082–7087.
King J, Thatcher N, Pickering C, et al. Sensitivity and specificity of immunohistochemical antibodies used to distinguish between benign and malignant pleural disease: a systematic review of published reports. Histopathology. 2006;49:561–568.
Attanoos RL, Griffin A, Gibbs AR. The use of immunohistochemistry in distinguishing reactive from neoplastic mesothelium. A novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet-derived growth factor-receptor, P-glycoprotein and Bcl-2. Histopathology. 2003;43:231–238.
Churg A, Colby TV, Cagle P, et al. The separation of benign and malignant mesothelial proliferations. Am J Surg Pathol. 2000;24:1183–1200.
Nautiyal N, Bhardwaj A, Acharya S, et al. Diagnostic utility of epithelial membrane antigen (EMA) and calretinin (CAL) in effusion cytology. J Clin Diagn Res. 2017;11:EC36–EC39.
Hasteh F, Lin GY, Weidner N, et al. The use of immunohistochemistry to distinguish reactive mesothelial cells from malignant mesothelioma in cytologic effusions. Cancer Cytopathol. 2010;118:90–96.
Sheffield BS, Hwang HC, Lee AF, et al. BAP1 immunohistochemistry and p16 FISH to separate benign from malignant mesothelial proliferations. Am J Surg Pathol. 2015;39:977–982.
Shinozaki-Ushiku A, Ushiku T, Morita S, et al. Diagnostic utility of BAP1 and EZH2 expression in malignant mesothelioma. Histopathology. 2017;70:722–733.
Yoshikawa Y, Sato A, Tsujimura T, et al. Frequent deletion of 3p21.1 region carrying semaphorin 3G and aberrant expression of the genes participating in semaphorin signaling in the epithelioid type of malignant mesothelioma cells. Int J Oncol. 2011;39:1365–1374.
Kinoshita Y, Hida T, Hamasaki M, et al. A combination of MTAP and BAP1 immunohistochemistry in pleural effusion cytology for the diagnosis of mesothelioma. Cancer. 2017;126:54–63.
Andrici J, Sheen A, Sioson L, et al. Loss of expression of BAP1 is a useful adjunct, which strongly supports the diagnosis of mesothelioma in effusion cytology. Mod Pathol. 2015;28:1360–1368.
Andrici J, Jung J, Sheen A, et al. Loss of BAP1 expression is very rare in peritoneal and gynecologic serous adenocarcinomas and can be useful in the differential diagnosis with abdominal mesothelioma. Hum Pathol. 2016;51:9–15.
Chapel DB, Husain AN, Krausz T, et al. PAX8 expression in a subset of malignant peritoneal mesotheliomas and benign mesothelium has diagnostic implications in the differential diagnosis of ovarian serous carcinoma. Am J Surg Pathol. 2017;41:1675–1682.
Battaglia A. The importance of multidisciplinary approach in early detection of BAP1 tumor predisposition syndrome: clinical management and risk assessment. Clin Med Insights Oncol. 2014;8:37–47.
Carbone M, Ferris LK, Baumann F, et al. BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs. J Transl Med. 2012;10:179.
Farley MN, Schmidt LS, Mester JL, et al. A novel germline mutation in BAP1 predisposes to familial clear-cell renal cell carcinoma. Mol Cancer Res. 2013;11:1061–1071.
Wadt K, Choi J, Chung JY, et al. A cryptic BAP1 splice mutation in a family with uveal and cutaneous melanoma, and paraganglioma. Pigment Cell Melanoma Res. 2012;25:815–818.
Abdel-Rahman MH, Pilarski R, Cebulla CM, et al. Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers. J Med Genet. 2011;48:856–859.
Ohar JA, Cheung M, Talarchek J, et al. Germline BAP1 mutational landscape of asbestos-exposed malignant mesothelioma patients with family history of cancer. Cancer Res. 2016;76:206–215.